Brief: Sequana Medical: Completion Of Pre-Clinical Studies With Second-Generation DSR Product For Congestive Heart Failure

Sequana Medical NV

08/02/2023 06:11

Feb 8 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES SUCCESSFUL COMPLETION OF
PRE-CLINICAL
STUDIES WITH ITS SECOND-GENERATION DSR PRODUCT FOR CONGESTIVE
HEART FAILURE
    * DATA FROM GLPI ANIMAL STUDIES DEMONSTRATE SAFETY OF
SECOND-GENERATION DSRII PRODUCT (DSR 2.0)
    * DATA FROM PHASE 1 STUDYOF DSR 2.0 IN MEXICO (CHIHUAHUA)
ANDINDIII FILING TO US FDA EXPECTED IN Q1 2023
    * PLANNING TO START MOJAVE, A US PHASE 1/2A RANDOMIZED
CONTROLLED
MULTI-CENTERSTUDY OF DSR 2.0,IN Q2 2023

Source text for Eikon:  ID:nGNX5BLtLC 
Further company coverage:  SEQUA.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))